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Abstract  37 
Background: According to the textbooks, the ketotic glycogen storage disease (GSD) types O, 38 
III, VI, IX and XI are associated with fasting ketotic hypoglycemia and considered milder as 39 
gluconeogenesis is intact.  40 
Methods: Retrospective cohort study of biochemical profiles from supervised clinical fasting 41 
studies performed in ketotic GSD patients in our metabolic center. For data analysis, 42 
hypoglycemia was defined as plasma glucose concentration <2.6 mmol/L. Total KB was defined 43 
as the sum of blood acetoacetate and β-hydroxybutyrate concentrations. If the product of glucose 44 
and KB concentrations was greater than 10, a ketolysis defect was suspected.  45 
Results: Data could be collected from 13 fasting studies in 12 patients with GSD III (n=4), GSD 46 
VI (n=3) and GSD IX (n=5). Six patients remained normoglycemic with median glucose 47 
concentration of 3.9 mmol/L [range: 2.8-4.6 mmol/L] and median total KB concentration of 1.9 48 
mmol/L [range: 0.6-5.1 mmol/L]. The normoglycemic patients included type VI (3 out of 3) and 49 
type IX (3 out of 5) patients. All type III patients developed ketotic hypoglycemia. Interestingly, 50 
in five patients (1 GSD III, 1 GSD VI and 3 GSD IX), the biochemical profile suggested a 51 
ketolysis defect. 52 
Conclusion: Normoglycemic ketonemia is a common biochemical presentation in patients with 53 
GSD types VI and IX and ketonemia can precede hypoglycemia in all studied GSD types. 54 
Therefore, GSD VI and IX should be added to the differential diagnosis of ketotic 55 
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Fasting intolerance (FI) is biochemically associated with hypoglycemia and/or metabolic 95 
acidosis, the latter often caused by increased concentrations of lactate and/or ketones. The 96 
differential diagnosis of childhood FI includes many endocrine disorders and inborn errors of 97 
metabolism, among which several types of glycogen storage disease (GSD).  98 
There are at least 13 types of GSD, which are classified according to the protein defect and organ 99 
distribution (Laforet et al 2012). The ketotic GSD types 0, III, VI, IX and XI are associated with 100 
fasting ketotic hypoglycemia and considered relatively mild compared to GSD type I because 101 
gluconeogenesis is intact. Traditionally ketotic hypoglycemia is considered the common 102 
diagnostic biochemical phenotype upon fasting in patients with ketotic GSD types (Laforet et al 103 
2012), although cohort studies have demonstrated that this is not always the case (Beauchamp et 104 
al 2007a; Beauchamp et al 2007b). It has recently been reported that ketotic GSD types can be 105 
easily misinterpreted as idiopathic ketotic hypoglycemia (Brown et al 2014).   106 
Regular monitoring of ketone bodies (KB) is recommended to titrate dietary management in 107 
ketotic GSD patients (Dagli et al 2010; Dagli and Weinstein 2009, Goldstein et al 2011), but 108 
experimental data are lacking. Therefore, we have performed this retrospective study of 109 
supervised clinical fasting studies in patients with ketotic GSD.  110 
 5 
Patients and Methods 111 
Subjects - The Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical 112 
Center Groningen is a tertiary metabolic center and a reference center for hepatic GSD patients. 113 
In the period 1993-2012, 539 supervised clinical fasting studies have been performed in 476 114 
patients. From this cohort all patients with ketotic GSD have been identified to perform a 115 
retrospective study of the biochemical profiles of their supervised clinical fasting studies. Data 116 
were anonymously retrieved from both the paper and electronic medical files. 117 
Fasting studies - Supervised clinical fasting studies were performed as described elsewhere 118 
(Bonnefont et al 1990; Van Veen et al 2011), for either diagnostic or therapeutic reasons, i.e. to 119 
titrate dietary management. Most diagnostic studies were performed before 2003, when plasma 120 
acylcarnitine profiling became available in our laboratory. Fasting studies were only performed 121 
in healthy patients in good nutritional condition. Subjects were admitted one day before the 122 
fasting test when they were <8 years of age. There was no limitation in water intake. After the 123 
last meal and an individually tailored period of fasting, an intravenous catheter was inserted for 124 
blood sampling at hourly intervals. Carefully supervised fasting was continued until glucose 125 
concentrations dropped below 2.6 mmol/L or until development of symptoms or signs of 126 
hypoglycemia.  127 
Statistical analysis - SPSS Statistics version 22.0 (IBM Corp., Armonk New York, USA) was 128 
used to calculate median and range for concentrations of glucose and KB. For data analysis, 129 
hypoglycemia was defined as plasma glucose concentration <2.6 mmol/L (Koh et al 1988). Total 130 
KB was defined as the sum of blood acetoacetate and β-hydroxybutyrate concentrations. If the 131 
product of glucose and KB concentrations was greater than 10, a ketolysis defect was suspected 132 
(Touati et al 2012).  133 
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Results  134 
Table 1 presents patients characteristics from 12 patients with GSD type III (n=4), type VI (n=3) 135 
and type IX (n=5), in whom a total of 13 supervised clinical fasting studies were performed. A 136 
fasting study was performed twice in patient 2 due to therapeutic reasons. For patient 2 and 12 no 137 
confirmatory molecular studies were available, however diagnosis was confirmed enzymatically, 138 
in leukocytes and erythrocytes, respectively. Patient 2 died at the age of 27 years by a car 139 
accident, his sister was homozygous for the c.2039G>A AGL founder mutation from the island 140 
of Aruba. 141 
Table 2 presents biochemical data during the fasting studies in the individual patients. Six 142 
patients showed normoglycemia during fasting, i.e. median blood glucose concentration in these 143 
patients were 3.9 mmol/L [range: 2.8-4.6 mmol/L] with median total KB concentration of 1.9 144 
mmol/L [range: 0.6-5.1 mmol/L]. The normoglycemic patients included type VI (3 out of 3) and 145 
type IX (3 out of 5) patients. All type III patients developed ketotic hypoglycemia, but 146 
interestingly, a remarkable increase in KB preceded hypoglycemia in these patients. Patient 4 147 
displayed hypoglycemia at the end of the fasting study, although her glucose concentration was 148 
not below 2.6 mmol/L during the last combined KB and glucose measurement. Patient 9 149 
developed hypoglycemia very quickly without clinical manifestations. In patient 11 the fasting 150 
study was terminated because of abdominal pain, nausea and vomiting, although plasma blood 151 
glucose concentrations were normal. At the moment of terminating the blood KB concentration 152 
was 3.3 mmol/L. For patient 12 only one combined measurement of blood glucose and KB 153 
concentration could be obtained, however it showed an elevated KB concentration of 0.6 154 
mmol/L already after three hours of fasting. Interestingly, the product of glucose and KB 155 
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suggested a ketolysis defect in 5 patients. One of these 5 patients underwent a fasting study for 156 
diagnostic purposes.  157 
Figure 1 presents concentrations of glucose and KB longitudinally in time for all fasted GSD 158 
type VI patients, demonstrating normoglycemia despite remarkable increase of KB 159 
concentrations.  160 
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Discussion  161 
This study demonstrates that normoglycemic ketonemia is a common biochemical phenotype in 162 
GSD type VI and IX and that ketonemia can precede hypoglycemia in all studied GSD types. 163 
This is important from both a diagnostic and management point of view. 164 
In this study normoglycemic ketonemia was presented by half of the GSD patients. Five out of 165 
twelve patients displayed a biochemical phenotype suggestive of a ketolysis defect (Bonnefont et 166 
al 1990). It was recently reported that especially GSD IX is an unappreciated cause of idiopathic 167 
ketotic hypoglycemia (Brown et al 2014). As this study also included diagnostic fasting studies, 168 
to our opinion it emphasizes the potential risk of underdiagnosing ketotic GSD. Ketotic GSD 169 
should therefore be included in the differential diagnosis of childhood FI associated 170 
normoglycemic ketonemia.  171 
Previously, supervised clinical fasting studies have played a central diagnostic role as an 172 
informative functional in vivo test (Bonnefont et al 1990), but nowadays these studies are 173 
considered obsolete. Moreover, fasting studies are relatively time-consuming, expensive, 174 
invasive and potentially dangerous. These fasting studies have merely been replaced after the 175 
introduction of new laboratory techniques, like acylcarnitine profiling (Millington et al 1990). 176 
More recently next generation sequencing and/or exome sequencing have developed into 177 
powerful diagnostic confirmatory tests (Wang et al 2012). In our experience there are few 178 
indications for the traditional clinical fasting studies, under exceptional circumstances and well-179 
controled conditions, to characterize the clinical in vivo implications for patients with unknown 180 
variations in the metabolome or genome.  181 
Several factors complicate the recognition of patients with ketotic GSD. During ‘quick’ physical 182 
examination at an emergency room, both the soft hepatomegaly (like in GSD types VI and IX) 183 
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and failure to thrive may be easily overlooked. Simple laboratory tests in blood are not routinely 184 
requested in stress samples from patients with FI. In untreated GSD patients, (a specific 185 
combination of) plasma concentrations of lactate, transaminases, uric acid, triglycerides and 186 
cholesterol is usually abnormal. In contrast, the traditional hormonal and secondary metabolic 187 
tests (like analysis of plasma acylcarnitines and urinary organic acids) are usually normal, even 188 
when samples are obtained under critical conditions. The above-mentioned investigations are 189 
important first-line tests in patients with FI to select candidates for confirmatory molecular 190 
and/or enzymatic testing for GSD.  191 
It is not known why some ketotic GSD patients display hypoglycemia and some do not. This 192 
variation is especially observed in GSD VI; hepatic phosphorylase deficiency, encoded by the 193 
PYGL gene (OMIM #232700) and GSD IX; hepatic phosphorylase b kinase deficiency, encoded 194 
by the PHKA2 gene (OMIM #300798; X-linked GSD IX), the PHKB gene (OMIM #172490), 195 
and PHKG2 gene (OMIM #172471) respectively. Beauchamp et al reported hypoglycemia in 5 196 
out of 13 GSD VI patients on either fasting or glucose loading tests (Beauchamp et al 2007a), 197 
while in GSD IX Beauchamp et al reported hypoglycemia as a presenting sign in 5 out of 15 198 
GSD IX patients (Beauchamp et al 2007b). The hypoglycemia in GSD IX patients included those 199 
with mutations in the PHKG2 gene, which is in line with Bali et al, who reported fasting 200 
hypoglycemia in all 5 patients with PHKG2 mutations (Bali et al 2014). This finding may be 201 
very well explained by the fact that mutations of the PHKG2 gene contains the catalytic site of 202 
hepatic phosphorylase b kinase.  203 
Uncooked cornstarch and protein are the keystones of dietary management in ketotic GSD, the 204 
latter serving as an alternative source for gluconeogenesis to maintain normoglycemia (Derks 205 
and Smit 2015). In ketotic GSD types, increased KB concentrations reflect increased 206 
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mitochondrial fatty acid oxidation, which is associated with activation of gluconeogenesis and 207 
secondary endogenous proteolysis from muscle tissue. Instead of maintenance of 208 
normoglycemia, prevention of increasing KB concentrations could therefore be regarded as a 209 
more relevant aim in optimizing metabolic control.  210 
At a relatively young age, one GSD III patient (patient 4) displayed a decrease in both KB and 211 
glucose concentrations with prolonged fasting. Hypoketosis has been reported before in GSD III 212 
patients (Seigel et al 2008; Clemente et al 2010), in whom exogenous carbohydrate requirements 213 
are still relatively high (Derks and Van Rijn 2015). We speculate that, as a consequence of 214 
dietary management with frequent high carbohydrate meals, there may have been a relatively 215 
high plasma insulin state together with high intracellular malonyl-CoA levels, physiologically 216 
inhibiting long-chain mitochondrial fatty acid oxidation at the level of carnitine 217 
palmitoyltransferase type I.  218 
This study has several limitations. First, data have retrospectively been retrieved from electronic 219 
and paper files, from fasting studies that have mostly been performed at least ten years ago. 220 
Second, fasting studies have been conducted in only a subset of our GSD patients, which could 221 
have introduced a selection bias. Third, these fasting studies originate from a period, in which the 222 
general opinion on dietary management and outcome parameters for ketotic GSD types was 223 
different. Last, the definition of hypoglycemia is debatable in several ways. We have defined 224 
hypoglycemia as a plasma glucose concentration <2.6 mmol/L, measured by calibrated meters 225 
with a constant factor of 1.11 for conversion between blood glucose and plasma glucose 226 
concentrations (D’Orazio et al 2005). Therefore, the plasma glucose concentrations are on 227 
average 11% higher compared to blood concentrations, depending on the hematocrit and the 228 
water component in blood. Also, hypoglycemia defined by a single number does not distinguish 229 
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the difference values at which an individual starts to compensate for inadequate glucose supply 230 
to the brain (Cornblath et al 2000).   231 
To date, in contrast with GSD III (Derks and Smit 2015; Kishnani et al 2010), there are no 232 
formal diagnostic and management guidelines for GSD VI and IX. Based on expert opinion, 233 
caregivers are advised to titrate dietary management, aiming at normoglycemia and maintenance 234 
of blood β-hydroxybutyrate concentrations lower than 0.3 mmol/L, measured by a portable blood 235 
ketone meter (Dagli et al 2010; Dagli and Weinstein 2009; Goldstein et al 2011). This study 236 
provides short-term, indirect biochemical evidence substantiating these management advices, but 237 
there is a lack of data on long-term clinical outcome parameters, like growth, liver size, 238 




























This is the first study that critically analyzed blood glucose and KB concentrations during fasting 266 
in ketotic GSD patients. Normoglycemic ketonemia is a common biochemical presentation in 267 
patients with GSD types VI and IX and ketonemia can precede hypoglycemia in all studied GSD 268 
types. Therefore, GSD VI and IX should be added to the differential diagnosis of ketotic 269 
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Legends Figures  336 
 337 
 338 
Figure 1. Longitudinal course of fasting in GSD type VI 339 
Legend:   Glucose concentration,   Ketone Bodies concentration, - - - Cut off 340 
point hypoglycemia.  341 
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Table 1. Patient characteristics 342 
Legend: 
a
: age during the fasting study in years and months, 
b
: M=male, F=female, -: 343 


















    Gene Exon 
nr 
Nucleotide 











 F IIIa AGL 
 


















- - - 
2 (2)* 16
6/12 
M IIIa - - - - - - - 
3* 22
5/12 
F IIIa AGL 17 c.2039G>A p.Trp680X 17 c.2039G>A p.Trp680X 
4 1
5/12 
M III AGL 13 c.1571G>A p.Arg524His - - - 
5 3
3/12 
M VI PYGL 3 c.385G>A p.Asp129Asn 20 c.2446C>T p.Arg816* 
6 4
10/12 
M VI PYGL 3 c.418C>G p.Leu140Val 11 c.1366G>A p.Val456Met 
7 1
10/12 
M VI PYGL 1 c.131G>A p.Arg44His 16 c.1900G>C p.Asp634His 
8 4
4/12 
M IX PHKA2 33 c.3614C>T p.Pro1205Leu    
9 1
7/12 
F IX PHKA2 33 c.3614C>T p.Pro1205Leu    
10 2
6/12 
M IX PHKA2 - DelXp22.13 -    
11 7
10/12 




M IX - - - - - - - 
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:KB is the sum of acetoacetate and β-353 
hydroxybutyrate, 
c
:suspect ketolysis defect is defined as a product of glucose and KB 354 
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